A study to evaluate the safety and efficacy of e-TNS for treating migraine | All the latest medical news on the portal Medznat.ru. :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

A study to evaluate the safety and efficacy of e-TNS for treating migraine

A study to evaluate the safety and efficacy of e-TNS for treating migraine A study to evaluate the safety and efficacy of e-TNS for treating migraine
A study to evaluate the safety and efficacy of e-TNS for treating migraine A study to evaluate the safety and efficacy of e-TNS for treating migraine

What's new?

e-TNS was found to be safe and effective for treating patients with acute migraine in this pilot study. Further studies will confirm its extensive application.

External trigeminal nerve stimulation (e-TNS) is a non-invasive medical device commonly used for the treatment of neurologic and psychiatric disorders. e-TNS is conducted via a transcutaneous supraorbital stimulator, which delivers mild electric signals to the affected organ. A prospective, open-labeled clinical trial was done at the Columbia University Headache Center with an aim to evaluate the safety and effectiveness of external trigeminal nerve stimulation (e-TNS) through a transcutaneous supraorbital stimulator for the acute treatment of migraine.

A total of 30 participants who were suffering from acute migraine problems with or without aura were included in the study. The patients were given a one-hour session of e-TNS. Pain intensity was calculated using a visual analogue scale (VAS) before the treatment, after one hour of the treatment and at two hours after treatment start. Rescue migraine medication consumption was noted at 2 and 24 hours.

Significant reduction in mean pain intensity was noted after the one-hour (57.1%) and two hours (52.8%) of e-TNS treatment. Within the two-hour observation period, none of the patients took rescue medication. 34.6% of patients took rescue medication within the 24-hour follow-up. The study reported no adverse events or subjective complaints.

Source:

Neuromodulation. 2017 Jun 5.

Article:

External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy

Authors:

Chou DE et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: